Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct 6:13:747050.
doi: 10.3389/fnagi.2021.747050. eCollection 2021.

Cognitive Dysfunctions in Glaucoma: An Overview of Morpho-Functional Mechanisms and the Impact on Higher-Order Visual Function

Affiliations
Review

Cognitive Dysfunctions in Glaucoma: An Overview of Morpho-Functional Mechanisms and the Impact on Higher-Order Visual Function

Alessandro Arrigo et al. Front Aging Neurosci. .

Abstract

Background: Glaucoma is a chronic, vision-threatening disease, and a major cause of legal blindness. The current view is no longer limited to the progressive optic nerve injury, since growing evidence strongly support the interpretation of glaucoma as a complex neurodegenerative disease. However, the precise pathogenic mechanisms leading to the onset and progression of central nervous system (CNS) impairment, and the functional consequences of this damage, are still partially understood. The main aim of this review is to provide a complete and updated overview of the current knowledge regarding the CNS involvement in glaucoma, and the possible therapeutic perspectives. Methods: We made a careful survey of the current literature reporting all the relevant findings related to the cognitive dysfunctions occurring in glaucoma, with specific remarks dedicated on the higher-order visual function impairment and the possible employment of neuroprotective agents. Results: The current literature strongly support the interpretation of glaucoma as a multifaceted chronic neurodegenerative disease, widely affecting the CNS. The cognitive impairment may vary in terms of higher-order functions involvement and in the severity of the degeneration. Although several neuroprotective agents are currently available, the development of new molecules represents a major topic of investigation for future clinical trials. Conclusions: Glaucoma earned the right to be fully considered a neurodegenerative disease. Glaucomatous patients may experience a heterogeneous set of visual and cognitive symptoms, progressively deteriorating the quality of life. Neuroprotection is nowadays a necessary therapeutic goal and a future promising way to preserve visual and cognitive functions, thus improving patients' quality of life.

Keywords: OCT; OCTA; cognitive impairment; glaucoma; neurodegeneration; neurodegenerative disease; neuroinflammation; neuroprotection.

PubMed Disclaimer

Conflict of interest statement

FB consultant for Alcon (Fort Worth, Texas, USA), Alimera Sciences (Alpharetta, Georgia, USA), Allergan Inc. (Irvine, California, USA), Farmila-Thea (Clermont-Ferrand, France), Bayer Shering-Pharma (Berlin, Germany), Bausch and Lomb (Rochester, New York, USA), Genentech (San Francisco, California, USA), Hoffmann-La-Roche (Basel, Switzerland), Novagali Pharma (Évry, France), Novartis (Basel, Switzerland), Sanofi-Aventis (Paris, France), Thrombogenics (Heverlee, Belgium), Zeiss (Dublin, California, USA). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Multimodal imaging in glaucoma. Fundus examination reveals an evident excavation of the optic disc (A). Structural optical coherence tomography (OCT) detects a remarkable thinning of retinal nerve fibers layer (RNFL) (B) and ganglion cells layer (GCL) (C). OCT angiography (OCTA) shows rarefied radial peripapillary capillary and deep capillary plexa (D,F respectively), and preserved superficial capillary plexus and choriocapillaris (E,G respectively). Multimodal imaging findings in a normal control is shown in (H–N), respectively.
Figure 2
Figure 2
Main alterations associated with neurodegenerative mechanisms in glaucoma.

References

    1. Abu-Amero K. K., Morales J., Bosley T. M. (2006). Mitochondrial abnormalities in patients with primary open-angle glaucoma. Invest. Ophthalmol. Vis. Sci. 47, 2533–2541. 10.1167/iovs.05-1639 - DOI - PubMed
    1. Armstrong R. A. (2008). Visual signs and symptoms of Parkinson’s disease. Clin. Exp. Optom. 91, 129–138. 10.1111/j.1444-0938.2007.00211.x - DOI - PubMed
    1. Armstrong R. A. (2011). Visual symptoms in Parkinson’s disease. Parkinsons Dis. 2011:908306. 10.4061/2011/908306 - DOI - PMC - PubMed
    1. Arrigo A., Calamuneri A., Milardi D., Mormina E., Rania L., Postorino E., et al. . (2017a). Visual system involvement in patients with newly diagnosed Parkinson disease. Radiology 285, 885–895. 10.1148/radiol.2017161732 - DOI - PubMed
    1. Arrigo A., Calamuneri A., Mormina E., Aragona P., Gaeta M., Quartarone A. (2017b). MRI findings of visual system alterations in Parkinson’s disease. Brain 140:e69. 10.1093/brain/awx244 - DOI - PubMed

LinkOut - more resources